Loading clinical trials...
Loading clinical trials...
A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma
Conditions
Interventions
Azacitidine
Laboratory Biomarker Analysis
+2 more
Locations
5
United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Chinese University of Hong Kong-Prince of Wales Hospital
Shatin, Hong Kong
National Cancer Center Hospital
Tokyo, Japan
National University Hospital Singapore
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Start Date
March 3, 2006
Primary Completion Date
April 19, 2013
Completion Date
March 31, 2027
Last Updated
April 13, 2026
NCT04458909
NCT03493451
NCT02168140
NCT01769222
NCT01523223
NCT01261247
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions